Cardiac Biomarkers Market Size to grow by USD 9024.1 million between 2024-2028

The Cardiac Biomarkers Market is segmented by Technology (Conventional laboratory testing and POC testing), Product (Troponin, BNP and NT-proBNP, CK-MB, Myoglobin, and Others), End-user (Hospitals and clinics and Diagnostic laboratories), and Geography (North America, Europe, Asia, and Rest of World (ROW)). As per the Global Forecast research report 2024-2028 published by Technavio, the market size is estimated to grow by USD 9024.1 million, at a CAGR of 12.88% during the forecast period. There are several companies that are contributing to the market as per this report. Increased focus on personalized medicine .

By Technology, the Conventional laboratory testing segment is projected to dominate the market size in 2024

In the cardiac biomarkers market, clinicians collect patient samples for laboratory analysis through conventional methods, ensuring secure packaging and transportation. These samples are subsequently sent to central laboratories for processing by skilled professionals. The turnaround time for results, which can range from 1-2 days, is primarily influenced by factors such as sample shipping, lab capacity, test complexity, and data dissemination. Ultimately, the entire process from sample collection to result delivery may span up to a week. This timeframe is largely due to the necessity of proper handling, shipping, and lab processing, as well as the need to ensure accurate and secure result transmission to healthcare providers.

For insights on company offerings- Request a sample report!

By Product, Troponin segment is expected to hold the largest market size for the year 2024

In the realm of cardiac biomarkers, troponins have emerged as a pivotal diagnostic tool due to their specificity in identifying cardiac muscle damage. These proteins, essential for the contraction of both cardiac and skeletal muscles, are particularly noteworthy for their high sensitivity in detecting myocardial infarction. Among troponins, troponin I and troponin T are most commonly utilized. Troponin I, with its prolonged presence in the bloodstream, is preferred over creatinine kinase-MB for its superior efficiency and extended diagnostic window. The growth of this segment is anticipated to be robust during the forecast period, driven by the increasing demand for accurate and timely diagnosis of cardiac conditions.

Why is North America forecasted to hold the largest regional market size in 2024?

The Cardiac Biomarkers Market represents a significant business opportunity due to the increasing prevalence of cardiovascular diseases and the growing demand for early and accurate diagnosis. Key players in this market include Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, who offer advanced solutions for the detection of cardiac biomarkers such as troponins and B-type natriuretic peptides. These companies invest heavily in research and development to bring innovative products to market, driving growth in the Cardiac Biomarkers Market.

To access the valuable insights - Download the Free Sample Report

Research Analysis Overview

The Cardiac Biomarkers Market refers to the industry dedicated to the production, development, and distribution of diagnostic solutions for detecting abnormalities in cardiac functioning using cardiac biomarkers. These biomarkers, which include proteins, hormones, and enzymes found in biological samples such as blood, play a crucial role in cardiac diagnostics, particularly in the detection of cardiovascular conditions and critical cardiac conditions. The patient base for cardiac biomarkers is vast, encompassing individuals with various cardiac conditions, from asymptomatic patients undergoing routine check-ups to those with advanced cardiovascular diseases like atherosclerosis. Epidemiological studies and clinical research have shown that the elderly population is at a higher risk for cardiovascular diseases, making them a significant target demographic. Quality control is essential in the cardiac biomarkers market to ensure accurate and reliable results. Diagnostic facilities, including hospital laboratories, rely on these tests to provide optimal patient care. Cardiology professionals use cardiac biomarkers to diagnose and monitor cardiac conditions, enabling timely intervention and improved patient outcomes. Overall, the cardiac biomarkers market continues to grow, driven by the increasing prevalence of cardiovascular diseases and the need for more precise and effective diagnostic solutions.

Market Research Overview

The global biotechnology market, a segment of the larger healthcare industry, encompasses businesses involved in the research and development or production of biotech products, including biologics, biosimilars, bio-betters, and biotech reagents. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving market growth include the increasing global population aging, with the proportion of individuals over 60 years projected to reach approximately 25% in the US by 2050 and Europe by 2030. - The Cardiac Biomarkers Market is experiencing significant growth, fueled by the . Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/